fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Allopurinol

6 general benefit · 4 not a benefit

Apo-Allopurinol Tablets · DIN 00402818 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Allopurinol Tablets · DIN 00402818 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-09-27 · brand APO-ALLOPURINOL TABLETS · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 100 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Allopurinol Tablets: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0780). What the ministry pays, not the patient.

Ministry pays: $0.0780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00402818)

Source record
DIN 00402818: Apo-Allopurinol Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 920000001; group id 894; item number 2146; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0780; ministry $0.0780 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00402818 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4276
Interchangeable products
Apo-Allopurinol · DIN 02402769 · not recorded Mar-Allopurinol · DIN 02396327 · $0.0780
Shortage status: resolved shortage (ended September 27, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00402818
Shortage record checked October 6, 2026

Mar-Allopurinol · DIN 02396327 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mar-Allopurinol · DIN 02396327 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-02-28 Health Canada: Marketed since 2013-04-17 · brand MAR-ALLOPURINOL · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 100 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Allopurinol: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0780). What the ministry pays, not the patient.

Ministry pays: $0.0780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396327)

Source record
DIN 02396327: Mar-Allopurinol Raw flags: chronicUseMed=Y, sec3=Y Item: 920000001; group id 894; item number 2146; lccId None; manufacturer id MAR Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0780; ministry $0.0780 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396327 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88136
Interchangeable products
Apo-Allopurinol · DIN 02402769 · not recorded Apo-Allopurinol Tablets · DIN 00402818 · $0.0780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396327
Shortage record checked October 6, 2026

Apo-Allopurinol Tablets · DIN 00479799 · 200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Allopurinol Tablets · DIN 00479799 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-09-27 · brand APO-ALLOPURINOL TABLETS · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 200 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Allopurinol Tablets: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1300). What the ministry pays, not the patient.

Ministry pays: $0.1300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00479799)

Source record
DIN 00479799: Apo-Allopurinol Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 920000028; group id 894; item number 2147; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1300; ministry $0.1300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00479799 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4303
Interchangeable products
Apo-Allopurinol · DIN 02402777 · not recorded Mar-Allopurinol · DIN 02396335 · $0.1300
Shortage status: shortage reported ended May 29, 2026 (report last updated May 29, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00479799
Shortage record checked October 6, 2026

Mar-Allopurinol · DIN 02396335 · 200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mar-Allopurinol · DIN 02396335 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-02-28 Health Canada: Marketed since 2013-04-17 · brand MAR-ALLOPURINOL · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 200 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Allopurinol: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1300). What the ministry pays, not the patient.

Ministry pays: $0.1300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396335)

Source record
DIN 02396335: Mar-Allopurinol Raw flags: chronicUseMed=Y, sec3=Y Item: 920000028; group id 894; item number 2147; lccId None; manufacturer id MAR Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1300; ministry $0.1300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396335 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88137
Interchangeable products
Apo-Allopurinol · DIN 02402777 · not recorded Apo-Allopurinol Tablets · DIN 00479799 · $0.1300
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396335
Shortage record checked October 6, 2026

Apo-Allopurinol Tablets · DIN 00402796 · 300 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Allopurinol Tablets · DIN 00402796 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-09-27 · brand APO-ALLOPURINOL TABLETS · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 300 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Allopurinol Tablets: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2125). What the ministry pays, not the patient.

Ministry pays: $0.2125 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00402796)

Source record
DIN 00402796: Apo-Allopurinol Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 920000013; group id 894; item number 2148; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2125; ministry $0.2125 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00402796 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4302
Interchangeable products
Apo-Allopurinol · DIN 02402785 · not recorded Mar-Allopurinol · DIN 02396343 · $0.2125 Zyloprim · DIN 00294322 · not recorded
Shortage status: resolved shortage (ended November 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00402796
Shortage record checked October 6, 2026

Mar-Allopurinol · DIN 02396343 · 300 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mar-Allopurinol · DIN 02396343 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-02-28 Health Canada: Marketed since 2013-04-17 · brand MAR-ALLOPURINOL · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 300 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Allopurinol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2125). What the ministry pays, not the patient.

Ministry pays: $0.2125 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396343)

Source record
DIN 02396343: Mar-Allopurinol Raw flags: chronicUseMed=Y, sec3=Y Item: 920000013; group id 894; item number 2148; lccId None; manufacturer id MAR Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2125; ministry $0.2125 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396343 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88138
Interchangeable products
Apo-Allopurinol · DIN 02402785 · not recorded Apo-Allopurinol Tablets · DIN 00402796 · $0.2125 Zyloprim · DIN 00294322 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396343
Shortage record checked October 6, 2026

Apo-Allopurinol · DIN 02402769 · 100 mg · tablet

Listed, not a benefitDormant since October 1, 2025 · checked October 5, 2026 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Allopurinol · DIN 02402769 Manufacturer: Apotex Inc.; listing date 2013-07-30 Health Canada: Dormant since 2025-10-01 · brand APO-ALLOPURINOL · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 100 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Allopurinol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02402769)

Source record
DIN 02402769: Apo-Allopurinol Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000001; group id 894; item number 2146; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02402769 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88760
Interchangeable products
Apo-Allopurinol Tablets · DIN 00402818 · $0.0780 Mar-Allopurinol · DIN 02396327 · $0.0780
Shortage status: resolved shortage (ended September 26, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02402769
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since October 1, 2025 — choose a marketed DIN from the same-category list.

Apo-Allopurinol · DIN 02402777 · 200 mg · tablet

Listed, not a benefitDormant since July 17, 2025 · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Allopurinol · DIN 02402777 Manufacturer: Apotex Inc.; listing date 2013-07-30 Health Canada: Dormant since 2025-07-17 · brand APO-ALLOPURINOL · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 200 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Allopurinol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02402777)

Source record
DIN 02402777: Apo-Allopurinol Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000028; group id 894; item number 2147; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02402777 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88761
Interchangeable products
Apo-Allopurinol Tablets · DIN 00479799 · $0.1300 Mar-Allopurinol · DIN 02396335 · $0.1300
Shortage status: resolved shortage (ended September 26, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02402777
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 17, 2025 — choose a marketed DIN from the same-category list.

Apo-Allopurinol · DIN 02402785 · 300 mg · tablet

Listed, not a benefitDormant since September 28, 2025 · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Allopurinol · DIN 02402785 Manufacturer: Apotex Inc.; listing date 2013-07-30 Health Canada: Dormant since 2025-09-28 · brand APO-ALLOPURINOL · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 300 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Allopurinol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02402785)

Source record
DIN 02402785: Apo-Allopurinol Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000013; group id 894; item number 2148; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02402785 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88762
Interchangeable products
Apo-Allopurinol Tablets · DIN 00402796 · $0.2125 Mar-Allopurinol · DIN 02396343 · $0.2125 Zyloprim · DIN 00294322 · not recorded
Shortage status: resolved shortage (ended September 26, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02402785
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 28, 2025 — choose a marketed DIN from the same-category list.

Zyloprim · DIN 00294322 · 300 mg · tablet

Listed, not a benefitDormant since August 4, 2017 · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Zyloprim · DIN 00294322 Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01 Health Canada: Dormant since 2017-08-04 · brand ALLOPURINOL · ATC M04AA01 ALLOPURINOL · form Tablet · route Oral · ingredients ALLOPURINOL 300 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zyloprim: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00294322)

Source record
DIN 00294322: Zyloprim Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000013; group id 894; item number 2148; lccId None; manufacturer id BWE Source form: Tab; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00294322 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1892
Interchangeable products
Apo-Allopurinol · DIN 02402785 · not recorded Apo-Allopurinol Tablets · DIN 00402796 · $0.2125 Mar-Allopurinol · DIN 02396343 · $0.2125
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00294322
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 4, 2017 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M04AA): coverage varies; not interchangeable

  • Febuxostat (Uloric): not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

FEBUXOSTAT

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 80mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-ALLOPURINOL TABLETS (Allopurinol) is indicated for: • Treatment of gout, either primary, or secondary to hyperuricemia which occurs in blood dyscrasias and their therapy. • Treatment of primary or secondary uric acid nephropathy, with or without accompanying signs or symptoms of gout. • Prophylactically, to prevent tissue urate deposition or renal calculi in patients with leukemias, lymphomas or other malignancies, receiving antineoplastic treatment (radiation or cytotoxic drugs) which might induce increased uricemia levels. Also in the therapy and prophylaxis of acute urate nephropathy and resultant renal failure in patients with neoplastic disease who are particularly susceptible to hyperuricemia and uric acid stone formation (especially after radiation therapy or use of antineoplastic drugs). • Prevention of the occurrence and recurrence of uric acid stones or gravel and renal calcium lithiasis in patients with hyperuricemia and/or hyperuricosuria. 1.1 Pediatrics Pediatrics (<18 years of age): Allopurinol tablets are contraindicated in children with the exception of those with hyperuricemia secondary to malignancy or with Lesch… https://pdf.hres.ca/dpd_pm/00076177.PDF PM date: JUL 05, 2024 Source product: APO-ALLOPURINOL TABLETS; DIN 00402796; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Allopurinol Tablets · DIN 00479799 Shortage status: shortage reported ended 2026-05-29 (report last updated 2026-05-29); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00479799

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Apo-Allopurinol, Zyloprim: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026